| Article ID | Journal | Published Year | Pages | File Type |
|---|---|---|---|---|
| 8725015 | Clinical Gastroenterology and Hepatology | 2018 | 34 Pages |
Abstract
Analysis of blood samples from patients with AD/ACLF participating in a feasibility study of 20% HAS infusions has shown that infusions to raise serum albumin above 30 g/L reversed plasma-mediated immune dysfunction by binding and inactivating PGE2. We also describe a method to classify the inflammatory response in AD/ACLF, based on lipid profile, which could improve identification of patients most likely to respond to HAS treatment. A randomized controlled trial is needed to determine whether these effects of HAS reduce infections in AD/ACLF. Trial registered with European Medicines Agency (EudraCT 2014-002300-24) and adopted by NIHR (ISRCTN14174793).
Keywords
Related Topics
Health Sciences
Medicine and Dentistry
Gastroenterology
Authors
Louise China, Alexander Maini, Simon S. Skene, Zainib Shabir, Yvonne Sylvestre, Romain A. Colas, Lucy Ly, Natalia Becares Salles, Vittorio Belloti, Jesmond Dalli, Derek W. Gilroy, Alastair O'Brien,